Glaukos Q1 net sales rise 9% to $73.9M; guides 2023 sales up; GAAP net loss widens to $34.6M

GLAUKOS Corp

2023-Q1 EPS reported -$0.72 revenue$73,899,000

Q1 2023 net sales $73.9M (+9% YoY); glaucoma $56.2M (+9%), corneal health $17.7M (+10%).
GAAP net loss $34.6M ($0.72 loss per share) vs net income $5.4M ($0.11) in Q1 2022.
Non-GAAP net loss $28.4M ($0.59) vs prior-year non-GAAP net loss $18.1M ($0.38).
Raised 2023 net sales guidance to $295-300M from $290-295M.
Operating expenses increased sharply: SG&A +22%, R&D +31%; ended Q1 with $325M cash.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GLAUKOS Corp reported the first quarter ended March 31, 2023 results: revenue $73.9 million, net income $34.6 million, EPS ($0.72) per diluted share. Guidance raised.

Period: the first quarter ended March 31, 2023
Revenue: $73.9 million
Net income: $34.6 million
EPS: ($0.72) per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2023. Key highlights include: ● Net sales of $73.9 million in Q1 2023 increased 9% year-over-year on a reported basis and 11% year-over-year on a constant currency basis. ● Glaucoma net sales of $56.2 million in Q1 2023 increased 9%

View on SEC.gov

Browse all earnings releases →

GLAUKOS Corp filing history →

Source: SEC EDGAR

accession 0001558370-23-007832

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.